Shanghai Kaibao Pharmaceutical (300039) - Total Liabilities
Based on the latest financial reports, Shanghai Kaibao Pharmaceutical (300039) has total liabilities worth CN¥308.94 Million CNY (≈ $45.21 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Shanghai Kaibao Pharmaceutical (300039) long-term investment share to see how much of total assets are deployed in long-term investments.
Shanghai Kaibao Pharmaceutical - Total Liabilities Trend (2006–2025)
This chart illustrates how Shanghai Kaibao Pharmaceutical's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Shanghai Kaibao Pharmaceutical assets under control.
Shanghai Kaibao Pharmaceutical Competitors by Total Liabilities
The table below lists competitors of Shanghai Kaibao Pharmaceutical ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Worldline SA
PA:WLN
|
France | €8.60 Billion |
|
Zhejiang Zanyu Technology Co Ltd
SHE:002637
|
China | CN¥4.75 Billion |
|
Sheela Foam Limited
NSE:SFL
|
India | Rs18.57 Billion |
|
DBV Technologies
NASDAQ:DBVT
|
USA | $62.80 Million |
|
Karnov Group AB
ST:KAR
|
Sweden | Skr4.36 Billion |
|
Groupon Inc
NASDAQ:GRPN
|
USA | $671.75 Million |
|
Viridien
PA:VIRI
|
France | €1.67 Billion |
|
Kunming Chuan Jin Nuo Chemical Co Ltd
SHE:300505
|
China | CN¥1.73 Billion |
Liability Composition Analysis (2006–2025)
This chart breaks down Shanghai Kaibao Pharmaceutical's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 300039 equity financing ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.36 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shanghai Kaibao Pharmaceutical's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shanghai Kaibao Pharmaceutical (2006–2025)
The table below shows the annual total liabilities of Shanghai Kaibao Pharmaceutical from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥359.64 Million ≈ $52.63 Million |
-13.43% |
| 2024-12-31 | CN¥415.45 Million ≈ $60.79 Million |
-24.02% |
| 2023-12-31 | CN¥546.82 Million ≈ $80.02 Million |
+9.75% |
| 2022-12-31 | CN¥498.24 Million ≈ $72.91 Million |
+60.25% |
| 2021-12-31 | CN¥310.90 Million ≈ $45.50 Million |
+4.00% |
| 2020-12-31 | CN¥298.96 Million ≈ $43.75 Million |
+9.51% |
| 2019-12-31 | CN¥273.01 Million ≈ $39.95 Million |
+4.10% |
| 2018-12-31 | CN¥262.26 Million ≈ $38.38 Million |
-16.55% |
| 2017-12-31 | CN¥314.26 Million ≈ $45.99 Million |
-4.07% |
| 2016-12-31 | CN¥327.61 Million ≈ $47.94 Million |
-22.21% |
| 2015-12-31 | CN¥421.16 Million ≈ $61.63 Million |
+80.97% |
| 2014-12-31 | CN¥232.72 Million ≈ $34.05 Million |
+41.29% |
| 2013-12-31 | CN¥164.72 Million ≈ $24.10 Million |
+15.76% |
| 2012-12-31 | CN¥142.29 Million ≈ $20.82 Million |
+20.61% |
| 2011-12-31 | CN¥117.97 Million ≈ $17.26 Million |
-11.56% |
| 2010-12-31 | CN¥133.39 Million ≈ $19.52 Million |
-33.04% |
| 2009-12-31 | CN¥199.20 Million ≈ $29.15 Million |
+93.49% |
| 2008-12-31 | CN¥102.95 Million ≈ $15.06 Million |
+21.63% |
| 2007-12-31 | CN¥84.64 Million ≈ $12.39 Million |
+17.89% |
| 2006-12-31 | CN¥71.80 Million ≈ $10.51 Million |
-- |
About Shanghai Kaibao Pharmaceutical
Shanghai Kaibao Pharmaceutical CO.,Ltd engages in the research, development, production, and sale of modern traditional Chinese medicines primarily in China. The company offers heat-clearing and detoxifying products, such as Tanreqing Injection for wind-heat in the lungs with phlegm-heat obstructing the lungs, early-stage pneumonia, acute bronchitis, acute exacerbations of chronic bronchitis, and… Read more